News

  • HOME
  • News
  • 2026
  • Asahi Kasei Bioprocess Featured in GEN: Hiroki Fukutomi Discusses the Future of Virus Filtration for Next-Generation Biologics

Asahi Kasei Bioprocess Featured in GEN: Hiroki Fukutomi Discusses the Future of Virus Filtration for Next-Generation Biologics

Nov 18, 2026

We are pleased to share that Hiroki Fukutomi, Manager of the Scientific Affairs Group at Asahi Kasei Life Science Corporation, was recently featured in an article published by GEN (Genetic Engineering & Biotechnology News) discussing how virus filtration technologies are evolving to support intensified bioprocessing and emerging biologic modalities such as bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-fusion proteins.

 

The article, "How Virus Filtration Is Keeping Pace with Next-Generation Biologics," explores the critical role of virus filtration in modern biopharmaceutical manufacturing and how advances in membrane design are helping manufacturers address the challenges associated with increasingly complex biologics. As new therapeutic formats continue to emerge, virus filtration must not only ensure robust viral safety but also support higher productivity, improved process efficiency, and compatibility with intensified and continuous manufacturing approaches.

The interview covers historical limitations in virus filtration, including throughput constraints, filter fouling, difficult-to-process feed streams, and challenges associated with low-flux operation. It also highlights how innovations in membrane structure and surface chemistry are enabling higher flux, improved pressure tolerance, and reliable virus retention without compromising process robustness.

 

Where Virus Filtration Has Been Limited

Historically, the constraints have not been a matter of throughput alone. Prefiltration is often required to mitigate premature fouling of virus-retentive filters, adding development work and increasing the number of consumables to be managed. Feed streams that are intrinsically difficult to filter have typically been addressed with hydrophilic membrane materials, but a relatively low operating pressure limit can restrict achievable flux and require larger membrane area or extended filtration time. And in continuous manufacturing, where filtration proceeds over long periods at low flux, maintaining reliable virus retention becomes a design question in its own right.

 

Supporting Intensified Bioprocessing

Intensified bioprocessing strategies require downstream operations that can keep pace with higher manufacturing throughput while maintaining viral safety. Advanced virus filtration technologies help reduce filtration time, simplify processing, and support efficient manufacturing at commercial scale.

 

Supporting Next-Generation Biologics

Novel therapeutic modalities often present unique filtration challenges due to increased molecular complexity and aggregation tendencies. Virus filtration solutions capable of delivering robust performance across a broad range of molecule types are becoming increasingly important for the successful development and manufacture of these therapies.

 

Supporting Continuous Manufacturing

As continuous and semi-continuous bioprocessing approaches gain momentum, virus filters must provide reliable virus retention and stable filtration performance during extended operation. Advanced membrane technologies are helping manufacturers integrate virus filtration into modern manufacturing platforms while maintaining operational efficiency.

 

At Asahi Kasei Bioprocess, we remain committed to helping biopharmaceutical manufacturers address evolving manufacturing challenges through innovative virus filtration technologies and scientific expertise that support safe, efficient, and flexible biologics production.

 

Read the full article How Virus Filtration Is Keeping Pace with Next-Generation Biologics